Literature DB >> 24961742

Viral kinetic modeling: state of the art.

Laetitia Canini1, Alan S Perelson.   

Abstract

Viral kinetic (VK) modeling has led to increased understanding of the within host dynamics of viral infections and the effects of therapy. Here we review recent developments in the modeling of viral infection kinetics with emphasis on two infectious diseases: hepatitis C and influenza. We review how VK modeling has evolved from simple models of viral infections treated with a drug or drug cocktail with an assumed constant effectiveness to models that incorporate drug pharmacokinetics and pharmacodynamics, as well as phenomenological models that simply assume drugs have time varying-effectiveness. We also discuss multiscale models that include intracellular events in viral replication, models of drug-resistance, models that include innate and adaptive immune responses and models that incorporate cell-to-cell spread of infection. Overall, VK modeling has provided new insights into the understanding of the disease progression and the modes of action of several drugs. We expect that VK modeling will be increasingly used in the coming years to optimize drug regimens in order to improve therapeutic outcomes and treatment tolerability for infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24961742      PMCID: PMC4210370          DOI: 10.1007/s10928-014-9363-3

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  92 in total

Review 1.  Modelling viral and immune system dynamics.

Authors:  Alan S Perelson
Journal:  Nat Rev Immunol       Date:  2002-01       Impact factor: 53.106

2.  Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice.

Authors:  Gabrielle T Belz; Dominik Wodarz; Gabriela Diaz; Martin A Nowak; Peter C Doherty
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis.

Authors:  Roland R Regoes; E Frances Bowen; Alethea V Cope; Dehila Gor; Aycan F Hassan-Walker; H Grant Prentice; Margaret A Johnson; Paul Sweny; Andrew K Burroughs; Paul D Griffiths; Sebastian Bonhoeffer; Vincent C Emery
Journal:  Proc Biol Sci       Date:  2006-08-07       Impact factor: 5.349

4.  Towards a quantitative understanding of the within-host dynamics of influenza A infections.

Authors:  Andreas Handel; Ira M Longini; Rustom Antia
Journal:  J R Soc Interface       Date:  2009-05-27       Impact factor: 4.118

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

6.  A dynamical model of human immune response to influenza A virus infection.

Authors:  Baris Hancioglu; David Swigon; Gilles Clermont
Journal:  J Theor Biol       Date:  2006-12-19       Impact factor: 2.691

7.  Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin.

Authors:  Jennifer E Layden-Almer; Ruy M Ribeiro; Thelma Wiley; Alan S Perelson; Thomas J Layden
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

8.  Effects of aging on influenza virus infection dynamics.

Authors:  Esteban A Hernandez-Vargas; Esther Wilk; Laetitia Canini; Franklin R Toapanta; Sebastian C Binder; Alexey Uvarovskii; Ted M Ross; Carlos A Guzmán; Alan S Perelson; Michael Meyer-Hermann
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

9.  A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.

Authors:  Bambang S Adiwijaya; Tara L Kieffer; Joshua Henshaw; Karen Eisenhauer; Holly Kimko; John J Alam; Robert S Kauffman; Varun Garg
Journal:  PLoS Comput Biol       Date:  2012-01-05       Impact factor: 4.475

10.  Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model.

Authors:  Libin Rong; Jeremie Guedj; Harel Dahari; Daniel J Coffield; Micha Levi; Patrick Smith; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2013-03-14       Impact factor: 4.475

View more
  34 in total

Review 1.  Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers.

Authors:  Christoph Langenstein; Diana Schork; Klaus Badenhoop; Eva Herrmann
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

Review 2.  Applications of mechanistic modelling to clinical and experimental immunology: an emerging technology to accelerate immunotherapeutic discovery and development.

Authors:  L V Brown; E A Gaffney; J Wagg; M C Coles
Journal:  Clin Exp Immunol       Date:  2018-09       Impact factor: 4.330

3.  Mathematical modelling identifies the role of adaptive immunity as a key controller of respiratory syncytial virus in cotton rats.

Authors:  Darren Wethington; Olivia Harder; Karthik Uppulury; William C L Stewart; Phylip Chen; Tiffany King; Susan D Reynolds; Alan S Perelson; Mark E Peeples; Stefan Niewiesk; Jayajit Das
Journal:  J R Soc Interface       Date:  2019-11-27       Impact factor: 4.118

4.  A theoretical framework for transitioning from patient-level to population-scale epidemiological dynamics: influenza A as a case study.

Authors:  W S Hart; P K Maini; C A Yates; R N Thompson
Journal:  J R Soc Interface       Date:  2020-05-13       Impact factor: 4.118

Review 5.  Modelling hepatitis C therapy--predicting effects of treatment.

Authors:  Alan S Perelson; Jeremie Guedj
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-30       Impact factor: 46.802

6.  Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach.

Authors:  Frederik Graw; Danyelle N Martin; Alan S Perelson; Susan L Uprichard; Harel Dahari
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

7.  Incomplete inhibition of HIV infection results in more HIV infected lymph node cells by reducing cell death.

Authors:  Laurelle Jackson; Jessica Hunter; Sandile Cele; Isabella Markham Ferreira; Andrew C Young; Farina Karim; Rajhmun Madansein; Kaylesh J Dullabh; Chih-Yuan Chen; Noel J Buckels; Yashica Ganga; Khadija Khan; Mikael Boulle; Gila Lustig; Richard A Neher; Alex Sigal
Journal:  Elife       Date:  2018-03-20       Impact factor: 8.140

Review 8.  Modeling Viral Spread.

Authors:  Frederik Graw; Alan S Perelson
Journal:  Annu Rev Virol       Date:  2016-08-31       Impact factor: 10.431

Review 9.  Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.

Authors:  Vincent Madelain; Thi Huyen Tram Nguyen; Anaelle Olivo; Xavier de Lamballerie; Jérémie Guedj; Anne-Marie Taburet; France Mentré
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

10.  Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C.

Authors:  He-Chuan Wang; Yu-Peng Ren; Yue Qiu; Jenny Zheng; Gai-Ling Li; Chuan-Pu Hu; Tian-Yan Zhou; Wei Lu; Liang Li
Journal:  Acta Pharmacol Sin       Date:  2017-09-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.